No Data
No Data
Protalix BioTherapeutics' CFO Rubin to Leave
NYSE American New 52-Week Highs And Lows
Protalix Biotherapeutics Is Developing Innovative Treatments for Rare Diseases With Its Proprietary ProCellEx Plant Cell Expression System | NYSE-A:PLX
Protalix BioTherapeutics to Present at the IAccess Alpha Virtual Best Ideas Spring Conference 2025
Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?
IAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025